Clin Oncol | Volume 6, Issue 1 | Case Report | Open Access

Synchronous Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Case Report and Review of the Literature

Meng-Meng Qu and Jun-Qiang Lei*

Department of Radiology, The First Clinical Medical College of Lanzhou University, China

*Correspondance to: Jun-Qiang Lei 

Fulltext PDF

Abstract

Presence of synchronous double primary Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) (sdpHCC-ICC) located separately within a single liver is extremely rare. We reported a 49-year-old female with the diagnosis of HBV was admitted to our hospital. The levels of α-Fetoprotein (AFP) and Carbohydrate Antigen 19-9 (CA19-9) were found to be elevated.
Abdominal ultrasonography and enhanced computed tomography revealed two solid masses located in Segments (S) 4 and 6 of the liver. The preoperative diagnosis was multiple primary hepatocellular carcinomas. Hepatic resection of both segments was done. The resected specimens revealed the presence of well-defined tumors in segments 4 and 6. Histopathological examination confirmed the tumor of the 4th segment to be moderately and poorly differentiated ICC, and the tumor of the 6th segment to be poorly differentiated HCC. Immunohistochemically, the ICC in S4 was positive for CK19 and negative for Heppar-1, while the HCC in S6 was positive for Heppar-1 and negative for CK19. Unfortunately, metastasis to multiple organs and lymph nodes were observed 3 months later. The clinical characteristics of sdpHCC-ICC are usually atypical and nonspecific making its preoperative diagnosis quite difficult. The purpose of this study is to investigate the clinical, imaging, pathological characteristics and prognosis of patients with sdpHCC-ICC, in order to enhance our understanding of the disease and improve diagnostic and therapeutic effect.

Citation:

Qu M-M, Lei J-Q. Synchronous Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Case Report and Review of the Literature. Clin Oncol. 2021;6:1866..

Subscribe to Our Newsletter